Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: Primary results from TROPION-Breast01

In the phase 3 TROPION-Breast01 study, researchers assessed datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy in patients with inoperable/metastatic HR+ HER2- breast cancer who had evidence of disease progression on endocrine therapy or for whom endocrine therapy was unsuitable, and who had received one to two previous lines of chemotherapy in the inoperable/metastatic setting. Results showed a significant improvement in progression-free survival as well as a favorable safety profile in the Dato-DXd arm, compared with patients who received chemotherapy.